Molecular Interactions
Last updated: 2025 Jul 18
Total hit(s): 6213
S.No.
1
40613498
Hydrophobin-Fused SARS-CoV-2 RBD production in Nicotiana benthamiana L. for COVID-19 serology.
Future Sci OA
2025 Dec
3.25
1
2
40045463
The characterization of technical design of a virus-like structure (VLS) nanodelivery system as vaccine candidate against SARS-CoV-2 variants.
Hum Vaccin Immunother
2025 Dec
4.7
1
3
40381203
Safety and immunogenicity of SARS-CoV-2 protein subunit recombinant vaccine (Indovac(R)) in healthy populations aged 18 years and above in Indonesia: A phase I, observer-blind, randomized, controlled study.
Hum Vaccin Immunother
2025 Dec
4.7
1
4
40077853
Characterization of the binding features between SARS-CoV-2 5'-proximal transcripts of genomic RNA and nucleocapsid proteins.
RNA Biol
2025 Dec
1
5
40366666
A four-week study on the toxicity of repeated intramuscular administration of plant-based BA-CoV2-0301 vaccine against SARS-CoV-2 in Sprague-Dawley rats.
J Immunotoxicol
2025 Dec
1
6
40329514
Integrating immune library probing with structure-based computational design to develop potent neutralizing nanobodies against emerging SARS-CoV-2 variants.
MAbs
2025 Dec
10
1
7
40371698
Natural product sennoside B disrupts liquid-liquid phase separation of SARS-CoV-2 nucleocapsid protein by inhibiting its RNA-binding activity.
J Enzyme Inhib Med Chem
2025 Dec
8.6
1
8
39865693
Immunogenicity and safety of a COVID-19 DNA vaccine in healthy adults and elderly: A randomized, observer-blind, placebo-controlled phase 2 trial.
Hum Vaccin Immunother
2025 Dec
4.7
1
9
39720838
Immunogenicity and safety of SARS-CoV-2 recombinant protein vaccine (CHO cell) LYB001 as a heterologous booster following two- or three-dose inactivated COVID-19 vaccine in adults aged >/=18 years: interim results of a randomized, active-controlled, double-blinded, phase 3 trial.
Expert Rev Vaccines
2025 Dec
4.37
1
10
40590376
SARS-CoV-2 RNA-binding protein suppresses extracellular miRNA release.
RNA Biol
2025 Dec
1
11
40432512
Neutralizing antibody levels as a key factor in determining the immunogenic efficacy of the novel PEDV alpha coronavirus vaccine.
Vet Q
2025 Dec
8.5
1
12
40674170
In vivo antibody diversification targeting a conserved coronavirus epitope.
J Exp Med
2025 Oct 6
10.35
1
13
40529300
Delivery strategies for RNA-targeting therapeutic nucleic acids and RNA-based vaccines against respiratory RNA viruses: IAV, SARS-CoV-2, RSV.
Mol Ther Nucleic Acids
2025 Sep 9
1
14
40381868
The type of the first prime/boost vaccine against SARS-CoV-2 exerts long-term effects on the humoral immune response.
Clin Immunol
2025 Sep
3.368
1
15
40638074
Nucleotide-bound crystal structures of the SARS-CoV-2 helicase NSP13.
Acta Crystallogr F Struct Biol Commun
2025 Aug 1
1
16
40404003
Food-derived bioactive pigment phycocyanobilin binds to SARS-CoV-2 spike protein both covalently and noncovalently affecting its conformation and functionality.
Arch Biochem Biophys
2025 Aug
1
17
40625421
The dual threat: exploring the emergence of human metapneumovirus and SARS-CoV-2 coinfections in respiratory infections.
3 Biotech
2025 Aug
2.27
1
18
40642289
Engineering functionally-optimized aptamers against SARS-Cov-2 for blocking spike-ACE2 interaction and aptasensor detection.
Mater Today Bio
2025 Aug
1
19
40632195
Computational design and evaluation of low-toxicity saquinavir analogues targeting the catalytic dyad and oxyanion-hole loop of SARS-CoV-2 Mpro: insights from ensemble docking, molecular dynamics, dynamic undocking, and ADMET analysis.
Drug Chem Toxicol
2025 Jul 9
1
20
40628911
ADME analysis, metabolic prediction, and molecular docking of lipoic acid with SARS-CoV-2 Omicron spike protein.
Sci Rep
2025 Jul 8
4.12
1
21
40632654
Structural serology of polyclonal antibody responses to mRNA-1273 and NVX-CoV2373 COVID-19 vaccines.
Cell Rep
2025 Jul 8
7.7
1
22
40639387
Efficacy, immunogenicity, and safety of a next-generation mRNA-1283 COVID-19 vaccine compared with the mRNA-1273 vaccine (NextCOVE): results from a phase 3, randomised, observer-blind, active-controlled trial.
Lancet Infect Dis
2025 Jul 7
21.77
1
23
40621910
Structural and functional analyses of SARS-CoV-2 Nsp3 and its specific interactions with the 5' UTR of the viral genome.
Microbiol Spectr
2025 Jul 7
4.6
2
24
40619617
Engineered Dual-Function Antibody-Like Proteins to Combat SARS-CoV-2-Induced Immune Dysregulation and Inflammation.
Adv Sci (Weinh)
2025 Jul 6
1
25
40619452
Central nervous system and systemic inflammatory networks associated with acute neurological outcomes in COVID-19.
Sci Rep
2025 Jul 6
4.12
1